GENB
Generate Biomedicines, Inc. Common Stock
NASDAQ: GENB · HEALTHCARE · BIOTECHNOLOGY
$12.63
+2.02% today
Updated 2026-04-30
Market cap
$1.59B
P/E ratio
—
P/S ratio
49.75x
EPS (TTM)
$-2.18
Dividend yield
—
52W range
$11 – $16
Volume
0.6M
Generate Biomedicines, Inc. Common Stock (GENB) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$12.63
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $0.0B | $0.0B |
| EPS | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.